Novo Nordisk's pricing tactics while in the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, who may have accused the company of cost gouging, declaring the stark contrast involving U.S. selling prices and people in Europe and copyright. This led Novo Nordisk to conduc